# Amneal Pharmaceuticals, Inc. (AMRX) — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_affe1586b180861fca14 · retrieved 2026-08-11T16:09:38.039Z

## Overview
Amneal Pharmaceuticals, Inc. is a diversified, global biopharmaceutical company focused on expanding access to affordable and innovative medicines, with a portfolio of approximately 300 complex generic, specialty, and biosimilar medicines.

On August 10, 2026, Amneal Pharmaceuticals LLC (a subsidiary of Amneal Pharmaceuticals, Inc.) completed its acquisition of 100% of the membership interests of Kashiv BioSciences, LLC. At closing, Amneal paid $375,000,000 in cash (subject to purchase price adjustments for cash, operations funding, indebtedness, transaction expenses, and working capital) and issued 28,942,108 shares of Class A common stock to the sellers. The sellers are also eligible to receive up to $350,000,000 in contingent payments upon achievement of certain regulatory milestones for up to six designated Kashiv product candidates, and contingent royalty payments equal to 25% of annual aggregate gross profits for certain products exceeding specified hurdle amounts over a 12-year period following closing.

## Terms
- Counterparty: Kashiv BioSciences, LLC · Deal value: $375.0M · Consideration: mixed

## Key dates
- Announced 2026-08-03

## Timeline
- 2026-08-03 · 8-K (0001628280-26-051900): 8-K - Amneal Pharmaceuticals, Inc. — *Amneal Pharmaceuticals, Inc. is a pharmaceutical company that develops and manufactures pharmaceutical preparations.* On August 3, 2026, Amneal Pharmaceuticals LLC and its subsidiaries entered into Amendment No. 3 to their Term Loan Credit Agreement with JPMorgan Chase Bank, N.A. as administrative agent. Consenting lenders converted their existing term loans on a cashless basis into new Amendment No. 3 Term Loans totaling $2.039 billion, while JPMorgan provided an additional $45.2 million term loan to prepay non-converting lenders' loans, bringing the total Amendment No. 3 Term Loans to approximately $2.084 billion. The repricing reduced the applicable interest rate margin by 50 basis points to 1.50% for base-rate loans and 2.50% for SOFR-based loans. The company estimates annualized cash interest savings of approximately $12 million from this repricing. The maturity date of August 1, 2032 remains unchanged, and the company may enter into future repricing transactions without incurring a prepayment premium if such repricing occurs after February 3, 2027.
  https://www.sec.gov/Archives/edgar/data/1723128/0001628280-26-051900.txt
- 2026-08-10 · 8-K (0001140361-26-032014): 8-K - Amneal Pharmaceuticals, Inc. — *Amneal Pharmaceuticals, Inc. is a diversified, global biopharmaceutical company focused on expanding access to affordable and innovative medicines, with a portfolio of approximately 300 complex generic, specialty, and biosimilar medicines.* On August 10, 2026, Amneal Pharmaceuticals LLC (a subsidiary of Amneal Pharmaceuticals, Inc.) completed its acquisition of 100% of the membership interests of Kashiv BioSciences, LLC. At closing, Amneal paid $375,000,000 in cash (subject to purchase price adjustments for cash, operations funding, indebtedness, transaction expenses, and working capital) and issued 28,942,108 shares of Class A common stock to the sellers. The sellers are also eligible to receive up to $350,000,000 in contingent payments upon achievement of certain regulatory milestones for up to six designated Kashiv product candidates, and contingent royalty payments equal to 25% of annual aggregate gross profits for certain products exceeding specified hurdle amounts over a 12-year period following closing.
  https://www.sec.gov/Archives/edgar/data/1723128/0001140361-26-032014.txt

## Citations
- 0001628280-26-051900 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000162828026051900
- 0001140361-26-032014 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126032014